Pfizer and the Feds

The countdown to Brandweek is on! Join us, Sept. 12-16, to identify new growth opportunities, solve challenges and connect with power players. View the lineup and secure your pass.


WASHINGTON — Federal regulators ordered Pfizer Inc. to stop running a print advertisement for cholesterol-lowering drug Lipitor, saying the ad’s claim that Lipitor can cut the risk of heart disease is misleading.

The Food and Drug Administration told Pfizer (PFE) that an eight-page ad for Lipitor that recently ran in a medical journal creates “an overwhelming impression” that Lipitor can reduce the risk of developing coronary heart disease.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in